These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 24879340)
41. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
42. Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan. Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U BMC Cancer; 2013 Jun; 13():312. PubMed ID: 23806170 [TBL] [Abstract][Full Text] [Related]
43. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Nodin B; Zendehrokh N; Sundström M; Jirström K Diagn Pathol; 2013 Jun; 8():106. PubMed ID: 23800114 [TBL] [Abstract][Full Text] [Related]
47. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709 [TBL] [Abstract][Full Text] [Related]
48. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database. Liu J; Xu W; Li S; Sun R; Cheng W Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439 [No Abstract] [Full Text] [Related]
49. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Lalwani N; Prasad SR; Vikram R; Shanbhogue AK; Huettner PC; Fasih N Radiographics; 2011; 31(3):625-46. PubMed ID: 21571648 [TBL] [Abstract][Full Text] [Related]
54. Epigenetic biomarkers in epithelial ovarian cancer. Gloss BS; Samimi G Cancer Lett; 2014 Jan; 342(2):257-63. PubMed ID: 22245949 [TBL] [Abstract][Full Text] [Related]
55. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers. Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626 [TBL] [Abstract][Full Text] [Related]
56. Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples. Kim YM; Lee SW; Chun SM; Kim DY; Kim JH; Kim KR; Kim YT; Nam JH; van Hummelen P; MacConaill LE; Hahn WC; Jang SJ PLoS One; 2014; 9(6):e99451. PubMed ID: 24936796 [TBL] [Abstract][Full Text] [Related]
57. The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future. Al Bakir M; Gabra H Br Med Bull; 2014 Dec; 112(1):57-69. PubMed ID: 25473022 [TBL] [Abstract][Full Text] [Related]
58. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features. Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230 [TBL] [Abstract][Full Text] [Related]
59. A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Jia D; Liu Z; Deng N; Tan TZ; Huang RY; Taylor-Harding B; Cheon DJ; Lawrenson K; Wiedemeyer WR; Walts AE; Karlan BY; Orsulic S Cancer Lett; 2016 Nov; 382(2):203-214. PubMed ID: 27609069 [TBL] [Abstract][Full Text] [Related]
60. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]